Table 3. HIV infection: AIDS prevalence, burden of disease (in disability-adjusted life-years [DALYs]), attributable mortality, RCTs included in Cochrane systematic reviews and ongoing RCTs selected from International Clinical Trials Registries for high-income and low- and middle-income countries.
| Countries | Attributable DALYs (thousands) | Attributable mortality (thousands) | HIV infection prevalence(thousands) | Total RCTs | PT RCTs | NPT RCTs | Total ongoing RCTs | PT ongoing RCTs | NPT ongoing RCTs |
| n = 67 568 (%) | n = 2 440 (%) | n = 33 200(%) | n = 177(%) | n = 78(%) | n = 99(%) | n = 234(%) | n = 156(%) | n = 78(%) | |
| High-income countries | 445 (0.6) | 15 (0.6) | 2 100 (6.3) | 123 (69.5) | 40 (51.3) | 83 (83.8) | 157 (67.1) | 99 (63.5) | 58 (74.3) |
| Low- or middle-income countries | 67 141 (99.4) | 2 425 (99.4) | 31 100 (93.7) | 54 (30.5) | 38 (48.7) | 16 (16.2) | 77 (32.9) | 57 (36.5) | 20 (25.7) |
| • Sub-Saharan Africa | 56 795 (84.1) | 2 057 (84.3) | 22 500 (67.9) | 37 (20.9) | 29 (37.1) | 10 (10.1) | 40 (17.1) | 28 (17.9) | 12 (15.3) |
| • South Asia | 5 846 (8.7) | 214 (8.8) | 4 000 (12.0) | 1 (0.6) | 0 | 0 | 2 (0.9) | 0 | 2 (2.6) |
| • Latin America and Caribbean | 2 099 (3.1) | 74 (3.1) | 1 800 (5.4) | 5 (2.8) | 2 (2.6) | 2 (2.0) | 9 (3.8) | 7 (4.5) | 2 (2.6) |
| • East Asia and pacific | 2 026 (2.9) | 68 (2.8) | 800 (2.4) | 9 (5.1) | 5 (6.4) | 4 (4.1) | 12 (5.1) | 10 (6.4) | 2 (2.6) |
| • Eastern Europe and central Asia | 277 (0.4) | 8 (0.3) | 1 600 (4.8) | 0 | 0 | 0 | 2 (0.9) | 0 | 2 (2.6) |
| • Middle east and North Africa | 99 (0.2) | -- | -- | 0 | 0 | 0 | 0 | 0 | 0 |
| • Multiple regions | -- | 2 (1.1) | 2 (2.6) | -- | 12 (5.1) | 12 (7.7) | -- |
RCTs: randomized controlled trials. PT: pharmacologic intervention. NPT: nonpharmacologic intervention. GBD: global burden of disease.